Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Insulin Glargine versus Neutral Protamine Hagedorn Insulin for Treatment of Diabetes in Pregnancy

Open access
Smith, Jennifer, Manuck, Tracy, White, Jenifer, Merrill, David · 2009 · American Journal of Perinatology

Abstract

We compared maternal and neonatal outcomes in diabetic pregnancies treated with either insulin glargine or neutral protamine Hagedorn (NPH) insulin. We performed a retrospective chart review of diabetic pregnant patients using the Diabetes Care Center of Wake Forest University during the years 2000 to 2005. Outcomes of interest included maternal hemoglobin A1C, average fasting and 2-hour postprandial blood sugars, mode of delivery, birth weight, 5-minute Apgar score < 7, umbilical artery pH < 7.20, incidence of neonatal hypoglycemia, and pregnancy complications. A total of 52 diabetic pregnant patients were included in this study. Twenty-seven women used insulin glargine. A total of 13 women used insulin glargine during the first trimester. Glycemic control was similar in women who used NPH insulin and insulin glargine, as determined by hemoglobin A1C levels and mean blood sugar values. There were no differences in mode of delivery, average birth weight, or neonatal outcomes. Maternal and fetal/neonatal outcomes appear similar in pregnant diabetic women who use either NPH insulin or insulin glargine in combination with a short-acting insulin analogue to achieve adequate glycemic control during pregnancy. Insulin glargine appears to be an effective insulin analogue for use in women whose pregnancies are complicated by diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1055/s-0028-1095181

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 7

  1. [2]Silverman BL, Rizzo TA, Cho NH, Metzger BE. Long-term effects of intrauterine environment. The Northwestern University Diabetes in Pregnancy Center. Diabetes Care 1998;21:B142–B149
  2. [9]Di Cianni G, Volpe L, Lencioni C, et al. Use of insulin glargine during the first weeks of pregnancy in five type I diabetic women. Diabetes Care 2005;28:982–983 INSULIN GLARGINE VERSUS NPH INSULIN FOR DIABETES IN PREGNANCY/SMITH ET AL 61
  3. [10]Holstein A, Plasche A, Egberts EH. Use of insulin glargine during embryogenesis in a pregnant woman with type I diabetes. Diabet Med 2003;20:779–780
  4. [11]Devlin JT, Hothersall L, Wilkis JL. Use of insulin glargine during pregnancy in a type I diabetic woman. Diabetes Care 2002;25:1095–1096
  5. [14]Gallen IW, Roland JM, Chirayath HH. Survey of glargine use in 115 pregnant women with type I diabetes. Diabet Med 2008;25:165–169
  6. [17]Kurtzhals P, Schaffer L, Sorenson A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogues designed for clinical use. Diabetes 2000;49: 999–1005
  7. [22]Lauszus FF, Klebe JG, Bek T, Flyvbjerg A. Increased serum IGF-1 during pregnancy is associated with progression of diabetic retinopathy. Diabetes 2003;52:852–856

Cited by

See all 22

Metadata

Authors
Smith, J., Manuck, T., White, J., & Merrill, D.
Affiliations
  • Wake Forest University Health Sciences (US)
  • Atrium Health Wake Forest Baptist (US)
Venue
American Journal of Perinatology
Published
2008-10-31
Volume
26
Issue
01
Pages
057-062
ISSN
  • 0735-1631 (ISSN-L)
  • 1098-8785
OpenAlex
W1970481694
Cited by
22
References
20
Citations by year
2022: 1 · 2021: 1 · 2019: 2 · 2017: 2 · 2016: 1 · 2015: 2 · 2014: 1 · 2013: 3 · 2012: 3
FWCI
2.29
Type
journal article
Language
en
Open access
Locations
  • American Journal of Perinatology (publishedVersion)
  • PubMed (publishedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • UNC Libraries
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
Keywords
insulin glargine, neutral protamine Hagedorn insulin, diabetes in pregnancy, glycemic control, HbA1c, neonatal outcomes, neonatal hypoglycemia, birth weight, mode of delivery, insulin analogues, short-acting insulin, pregnancy complications
MeSH terms
Insulin Glargine, Adult, Apgar Score, Birth Weight, Blood Glucose, Carbon Dioxide, Eating, Fasting, Female, Gestational Age, Glycated Hemoglobin, Humans, Hydrogen-Ion Concentration, Hypoglycemia, Hypoglycemic Agents, Infant, Newborn, Insulin, Insulin, Isophane, Oxygen, Pregnancy, Pregnancy Complications, Pregnancy in Diabetics, Pregnancy Outcome, Retrospective Studies, Umbilical Arteries, Diabetes, Gestational, Delivery, Obstetric, Insulin, Long-Acting, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin Glargine versus Neutral Protamine Hagedorn Insulin for Treatment of Diabetes in Pregnancy. https://app.cochat.ai/papers/10.1055/s-0028-1095181
The paper
Smith, J., Manuck, T., White, J., & Merrill, D. (2009). Insulin Glargine versus Neutral Protamine Hagedorn Insulin for Treatment of Diabetes in Pregnancy. American Journal of Perinatology. https://doi.org/10.1055/s-0028-1095181

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.